NY Launches First State-Funded CBD/THC Study for IBD

Cannabis research in the United States has been stuck in a familiar loop for years: federal scheduling rules limit who can study the plant, private companies do most of the work for product-development reasons, and the resulting evidence base tilts toward small studies with narrow questions. State governments have largely watched from the sideline.

That changed this month. The New York State Office of Cannabis Management (OCM) has launched a first-of-its-kind state-funded observational study examining how oral CBD and THC affect quality of life in adults with moderate Inflammatory Bowel Disease (IBD), the agency announced in May 2026. Two of the country's largest medical cannabis operators — Vireo Health and Green Thumb Industries (GTI) — have signed on as the dispensing partners providing regulated, lab-tested cannabis products to enrolled patients.

It is the kind of study that has been called for repeatedly by clinicians, patient advocates, and even cannabis-cautious public health officials. And the fact that a state regulator is the convening authority — not a pharmaceutical company, not a single academic medical center — represents a meaningful shift in how cannabis research is organized in the U.S.

What the New York IBD cannabis study actually does

The full title of the study is "A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms." That mouthful describes a fairly standard observational research design with a few important features that make it unusual for cannabis.

It is prospective, meaning patients are enrolled and tracked forward in time rather than studied retrospectively from existing records. It is observational rather than a randomized clinical trial, so OCM is not assigning patients to specific dosing regimens or holding back a placebo arm. Instead, the study will follow adults with clinically confirmed moderate IBD as they take oral doses of CBD and THC obtained through New York's regulated medical cannabis program, and capture standardized quality-of-life measures over time.

For an under-studied area like cannabis and IBD, that design has real advantages. Randomized cannabis trials are notoriously difficult to run because of federal product restrictions, the variability of plant-derived medicines, and recruitment challenges among patients who often have access to cannabis outside the trial framework. An observational study using regulated, tested medical cannabis bypasses several of those headaches while still generating data that can guide later, more rigorous trials.

Dr. Nakesha Abel, OCM's Director of Scientific Programs & Research, is the principal investigator. In the agency's announcement, Abel framed the work this way: "Research like this helps move the conversation about cannabis from anecdotal experiences to measurable data-driven patient outcomes."

Why CBD, THC, and inflammatory bowel disease

The choice of IBD as the first OCM-funded research target is not random. Inflammatory bowel disease — primarily Crohn's disease and ulcerative colitis — affects an estimated 3 million Americans and produces a chronic-disease burden that current treatments often only partially address. Cannabis use is unusually common among IBD patients, with surveys consistently finding that 15-30% report using it at least occasionally to manage symptoms like pain, cramping, nausea, and appetite loss.

The pre-clinical and small-trial literature on CBD and THC in IBD has produced a string of intriguing-but-not-definitive findings. Multiple 2025 and 2026 studies have reported significant symptom relief in IBD patients using cannabinoids, including a Cornell-affiliated analysis suggesting symptom relief in roughly 87% of surveyed IBD patients who used cannabis. But most of that work has relied on patient self-report, retrospective records, or single-site recruitment, leaving regulators and clinicians without a reliable evidence base to point to.

A state-funded prospective observational study addresses two specific gaps. It standardizes the products patients are taking — because Vireo and GTI are providing regulated medical cannabis products with known cannabinoid profiles — and it standardizes how outcomes are measured across enrolled patients. Both are improvements on the typical cannabis-and-IBD literature.

The Vireo and Green Thumb Industries dispensing partnership

The decision to bring in two licensed multi-state operators as dispensing partners is itself a meaningful policy statement. It signals that OCM views the existing regulated medical cannabis program — and the major operators within it — as legitimate research infrastructure, not just retail.

Vireo Health and Green Thumb Industries are both well-established medical cannabis operators with a presence in New York. Their role in the study is to ensure enrolled patients have access to consistent, lab-tested CBD and THC products throughout the observation period. That continuity is critical for a study that is trying to draw inferences about cannabinoid effects: without product consistency, you cannot reliably attribute symptom changes to the cannabis at all. New York patients enrolled in the program can find their nearest dispensing partner through Budpedia's directory of verified cannabis dispensaries or our state-specific New York dispensaries hub.

OCM's announcement specifically commended both companies for their cooperation, language that suggests the agency wants to model what a regulator-operator-academic collaboration on cannabis research can look like. If the IBD study generates useful data, that template — state-funded design, OCM scientific oversight, MSO dispensing partners — could be replicated for chronic pain, PTSD, opioid-use disorder, or other conditions where cannabis use is widespread but evidence is thin.

Implications: what a state-run cannabis study unlocks

The federal rescheduling of marijuana to Schedule III earlier this year has begun to ease some of the historical barriers to cannabis research, but the resulting infrastructure is still being built. National administrative hearings on broader rescheduling are scheduled for late June 2026, and the academic research community is in the early stages of figuring out what new studies become feasible under the updated framework.

In that environment, a state cannabis regulator stepping forward to fund and coordinate its own observational research is significant for at least three reasons.

First, it produces real data on a real patient population using real, regulated products — exactly the kind of evidence that has been missing from policy debates about medical cannabis.

Second, it creates a model that other states with mature medical cannabis programs can study and replicate. New York is not the only state with a robust regulated market, deep MSO presence, and an active research office. If the OCM-Vireo-GTI partnership runs smoothly, expect similar designs to surface in other state programs over the next 12-24 months.

Third, it changes the political conversation. A state-funded observational study with a named principal investigator, named dispensing partners, and a registered protocol is much harder to dismiss as anecdote-driven advocacy. Even cannabis-skeptical policymakers tend to grant more weight to data that comes out of a regulator's scientific arm than to data from product manufacturers or patient surveys alone.

The IBD study is a pilot, and pilot studies have limits. The sample size will be modest, and observational designs cannot fully replace randomized trials when it comes to definitive efficacy claims. But the study answers a different question than efficacy — it answers what happens when adults with IBD use regulated CBD and THC products in a real-world setting, with standardized measurement. That answer is currently missing from the literature, and the absence of it has been a recurring problem for clinicians trying to advise patients about whether medical cannabis is worth trying.

Key Takeaways

• New York's Office of Cannabis Management has launched the first state-funded observational study examining oral CBD and THC in adults with moderate Inflammatory Bowel Disease, announced in May 2026.
• The study is titled "A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms," with Dr. Nakesha Abel as principal investigator.
• Vireo Health and Green Thumb Industries are the dispensing partners providing regulated, lab-tested medical cannabis products to enrolled patients.
• IBD affects roughly 3 million Americans, and existing cannabis-IBD research has been dominated by self-report and retrospective designs.
• The state-funded model could serve as a template for other regulated markets and shifts cannabis research infrastructure beyond pharma and academia.

Explore cannabis news, find dispensaries, and join the community at Budpedia.